Product Name
Option 1 / Option 2 / Option 3
Weekly Delivery
Product Discount (-$0)
COUPON1 (-$0)
£0
£0
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Cart is empty
Subtotal
£0
Total
£0

Struggling with Type 2 Diabetes Treatment?

Living with Type 2 Diabetes can be challenging, especially when it comes to finding the right treatment. Dr. Frank's team is here to help you navigate this journey and find the personalised treatment you need.

Learn More

If you have type 2 diabetes and resonate with any of the following situations. Book a free no-obligation call with us today...

Affected by the Ozempic Shortage

Missed Ozempic due to shortage in the last 12-18 months? Started on alternatives like Gliclazide or Insulin? We understand your frustration

Struggling to Meet Diabetes Targets

Have you been unable to achieve your diabetes target (HbA1c) despite trying Ozempic or other GLP1 agonist therapies like Rybelsus, Victoza, Bydureon, or Trulicity?

Inconsistent Supply of  Treatment

Are you currently on GLP1 agonist therapies (Ozempic, Rybelsus, Victoza, Bydureon, Trulicity) but facing challenges in consistently accessing your treatment?

Book Free Consultation

Dr Frank's Method

Weight Loss Medication

Discover the science behind GIP & GLP-1, our innovative medication designed to target three fundamental mechanisms for optimal weight management.

Specialist Weight Loss Nurses

Will guide + support you through your weight loss journey with monthly review clinics + unlimited well being calls.*

*costs may be incurred depending on your chosen service/subscription type

Exercise & Nutrition Support Pack

Accelerate your results + make informed decisions. Developed by Dr Franklin Joseph and our specialist dietitian.

Manage your diabetes with Dr. Frank's approach.

If you're unable to qualify for NHS treatment with Ozempic (Semaglutide) or Mounjaro (Tirzepatide), Dr. Frank can provide the help you need.

Your diabetes is well-controlled, which means you don't meet the criteria for treatment eligibility.

Your BMI and weight do not meet the necessary criteria for eligibility.

You're not currently taking three tablets for blood sugar control.

Book Free Consultation

Mounjaro

GIP & GLP-1 Medication

Prices start from:

£205.00

£129.00/month

£76 off when you sign-up to our newsletter
Free Shipping
Lose up to 20% in the first year
Cancel anytime
Dose escalation available
Start Assessment

Mounjaro

GIP & GLP-1 Medication

Prices start from:

£205.00

£129.00/month

£76 off when you sign-up to our newsletter
Free Shipping
Lose up to 15% in the first year
Cancel anytime
Dose escalation available
Start Assessment

Trusted by over 14,000+ patients

Jacqui

42lbs lost in 5 months

“I’m at my honeymoon weight which was in April 1978. I couldn’t be happier.”

Ethan

Lost 70lbs in 5 months

“I’ve never felt so comfortable in my own skin.”

Dimitra

Lost 56lbs in 8 months

“The sole solution that has been effective after my long struggle”

The Data

Make an informed decision based on the data collected.

Mounjaro 15 mg delivered double the mean weight reduction vs semaglutide 1 mg at week 40
Mounjaro Vs Semaglutide 1 mg

Comparing weight change: Wegovy Vs Mounjaro

The study found that Mounjaro  doses of 5 mg, 10 mg, and 15 mg helped people lose more weight than semaglutide 1 mg by the 40th week. Specifically, the 15 mg Mounjaro dose led to twice as much weight loss as the semaglutide dose by that time.*

Get Started1https://www.nejm.org/doi/full/10.1056/nejmoa2107519
Participants using GLP-1 medication lost 5 times more weight than with diet & exercise alone¹
Wegovy Vs Diet & Exercise Alone

Patients lose 15% body weight¹

Based on a 68-week clinical study of once-weekly injection of a GLP-1 receptor agonist compared to a placebo with 1961 participants.

Get Started¹ https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Mounjaro VS Placebo

Patients lose up to 20% body weight1

All 3 doses of once weekly mounjaro led to clinically meaningful and sustained weight reduction in obese adults

Get Started¹ https://www.nejm.org/doi/full/10.1056/NEJMoa2206038?